Trial Profile

A Randomized, Double-Blind, Placebo Controlled, Multi-Center Study of a Single Injection Cross-Linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (Cingal®) to Provide Symptomatic Relief of Osteoarthritis of the Knee

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 08 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Aug 2023 According to an Anika Therapeutics media release, company had a type-C meeting with the FDA in the second quarter and are actively engaging with them regarding next steps for U.S. regulatory approval.
28 Nov 2022 Status changed from active, no longer recruiting to completed.
01 Nov 2022 According to an Anika Therapeutics media release, the company will engage with the U.S. Food and Drug Administration (FDA) in the coming months on next steps for U.S. regulatory approval.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com